Overview

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of CC-220 in healthy subjects and to evaluate the relative bioavailability of a formulated CC-220 capsule
Phase:
Phase 1
Details
Lead Sponsor:
Celgene Corporation